This change highlights the MDS/MPN nature of the disease, while the absence of the terms “atypical CML” and “BCR::ABL1-negative” in the WHO classification avoids potential confusion with both classical CML and other Philadelphia-negative disorders [3]. This evidence concerns the gene BCR and myeloproliferative disorder.